Markets
markets

RIP Bill Ackman’s IPO

Life comes at you fast. Just 26 days ago, we wrote about Bill Ackman's plan to leverage his X account to help raise $25 billion for his new US closed-end fund, Pershing Square USA. But it appears that Ackman's $25 billion plan was too ambitious.

Yesterday, Bloomberg reported that Pershing Square had reduced its $25 billion target to around $2 billion, and now, Pershing Square has pulled its IPO entirely.

In a press release today, Ackman said, "Over the last seven weeks, we have met with many institutions and family offices, and held numerous town halls for Pershing Square USA, Ltd. While we have received enormous investor interest in PSUS, one principal question has remained:

Would investors be better served waiting to invest in the aftermarket than in the IPO?

This question has inspired us to reevaluate PSUS’s structure to make the IPO investment decision a straightforward one. We will report back once we are ready to launch a revised transaction.”

In hindsight, attempting to leverage one's X followers to raise a $25 billion fund was a stretch, even for one of America's most well-known investors.

In a press release today, Ackman said, "Over the last seven weeks, we have met with many institutions and family offices, and held numerous town halls for Pershing Square USA, Ltd. While we have received enormous investor interest in PSUS, one principal question has remained:

Would investors be better served waiting to invest in the aftermarket than in the IPO?

This question has inspired us to reevaluate PSUS’s structure to make the IPO investment decision a straightforward one. We will report back once we are ready to launch a revised transaction.”

In hindsight, attempting to leverage one's X followers to raise a $25 billion fund was a stretch, even for one of America's most well-known investors.

More Markets

See all Markets
markets
Nate Becker

Health insurance stocks lose steam as Trump says he’ll lobby insurers for lower prices

Shares of health insurance companies dropped Friday afternoon, as President Trump said he would ask insurers to meet with him in the coming weeks to seek lower prices.

Stocks including Humana, UnitedHealthcare, Cigna, CVS Health, and Elevance Health all either pared gains or went further into the red after Trump’s remarks, which came at the end of a press event to announce pricing deals with nine drugmakers.

“I’m going to call a meeting of the big insurance companies that have gotten so rich,” Trump said, noting that he would lobby them for lower prices.

“I would say that maybe with one talk, they would be willing to cut their prices by 50, 60, or 70%. They’ve made a fortune.”

markets

Rivian’s surge continues as stock reaches highest level since December 2023 on analyst upgrades

Shares of EV maker Rivian are on pace to close up double digits for the second day in a row on Friday as bullish investors pour into the stock following analyst upgrades.

Rivian shares were up more than 10% on Friday afternoon, with the stock climbing to its highest level since December 2023.

Webush’s Dan Ives boosted his Rivian price target by 56% to $25 in a note on Friday morning. The analyst wrote that 2026 is a “prove-me” year for the automaker, with its lower-cost R2 model set to launch in the first half.

Ives’s note follows a separate optimistic bit of analysis from Baird, which also boosted its Rivian price target to $25 in a note on Thursday.

If today's gains hold, Friday will mark the third day of double-digit gains for Rivian in the past six trading days. An “AI Day” event that saw the automaker detail autonomous updates and tease a robotaxi plan started the recent run.

markets
Luke Kawa

The neoclouds are shooting back up into the stratosphere

Investors’ faith in tech CEOs’ pursuit of digital God has seemingly been restored for now, sparking an intense rally in the speculative AI players that had been in full-on meltdown mode over concerns that the boom had passed its best-before date.

The data center companies colloquially known as the “neoclouds” — CoreWeave, Nebius, IREN, and Cipher Mining — are up more than double digits over the past two sessions, as of 10:40 a.m. ET.

The past 48 hours have brought a steady drumbeat of positive news for the AI theme.

CoreWeave received a vote of confidence from Wall Street as Citi resumed coverage with a buy rating and price target of $135. Oracle, the epicenter of AI credit concerns, has seen a reversal in its fortunes as it nears an acquisition of TikTok’s US operations. And OpenAI’s fundraising efforts appear be going so well that its reported valuation has gone up in back-to-back days.

Before that, Micron’s earnings reaffirmed the intense demand for AI compute, which continues to outstrip supply — a positive sign for the neoclouds. The macro backdrop is also turning perhaps a bit more in favor of lower interest rates, as CPI inflation came in well below expectations.

Snoop Dogg Performs At OVO Hydro Glasgow

Marijuana rescheduling could mean more investment in US weed stocks. There aren’t many ways in.

“Yes, institutional capital will go into the underlying names. The question is: How fast?" one weed company chairman said.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.